Negotiations for the sixth iteration of the Medical Device User Fee Amendments (MDUFA VI) have intensified as medical technology industry advocates and the Food and Drug Administration (FDA) grapple over transparency requirements, hiring commitments, and the fundamental financial triggers that govern the agency’s device review operations. In a series of high-stakes meetings held throughout early 2025, industry lobbyists have pushed for granular data regarding the FDA’s workforce, while the agency has sought to loosen certain fiscal restrictions that currently prevent it from accessing industry-provided funds if congressional appropriations fall short. These discussions, which will dictate the funding and performance goals for the Center for Devices and Radiological Health (CDRH) from October 2027 through September 2032, come at a precarious time for the agency following significant federal workforce reductions.
The Push for Granular Staffing Transparency
A primary point of contention in the current round of negotiations involves how the FDA reports its staffing levels to the industry that funds a significant portion of its operations. During a meeting on February 4, 2025, medtech industry representatives formally proposed updates to the MDUFA quarterly reporting requirements. The industry’s proposal would require the FDA to provide staffing levels broken down by specific offices within the CDRH. This level of detail is intended to allow manufacturers to see exactly where their user fee dollars are being allocated and whether specific product review branches—such as those handling cardiovascular, orthopedic, or neurological devices—are adequately staffed to meet performance goals.
The FDA’s response, delivered during a subsequent meeting on February 11, suggested a more generalized approach. The CDRH provided a counter-proposal offering center-level reporting rather than office-level reporting. Under the agency’s plan, the industry would receive data on the total number of employees within the device center, but would lack the visibility into specific departments that lobbyists are seeking. As of the latest meeting minutes, this issue remains a central point of negotiation, with industry groups arguing that center-level data obscures potential bottlenecks in specific high-demand review divisions.
The demand for transparency is fueled by a departure from recent reporting norms. While the September 2024 quarterly report included detailed staffing information and hiring efforts, the CDRH’s 2025 annual report notably omitted this data. Industry stakeholders view this lack of transparency as a regression, particularly as they are being asked to commit billions of dollars in fees over the next five-year cycle.
Reverting to MDUFA IV Hiring Commitments
Staffing has become a flashpoint in the MDUFA VI talks due to the tumultuous history of the current agreement, MDUFA V. The current framework included specific funding incentives tied to hiring performance, a mechanism designed to ensure the FDA aggressively expanded its workforce to keep pace with the increasing complexity of medical technology. However, the political landscape shifted dramatically last year when the Trump administration implemented broad cuts across the federal workforce, resulting in the loss of thousands of FDA employees.
These layoffs put the future of the user fee program in jeopardy, as the agency struggled to meet the hiring targets mandated by MDUFA V. In the February 11 meeting, the CDRH agreed to a commitment to hire consistent with the upcoming agreement, but with a significant caveat: the language would mirror that of MDUFA IV. Unlike the current agreement, MDUFA IV did not tie user fee revenue directly to hiring performance through financial incentives. By moving back to this older model, the FDA gains more flexibility in how it manages its workforce, but industry groups lose the leverage of "pay-for-performance" hiring. Despite this, industry groups have reportedly supported the change, likely recognizing the practical impossibility of meeting strict hiring quotas in the current federal employment climate.
International Fee Restructuring and Trade Implications
The negotiations are also addressing the financial burden placed on overseas medical device manufacturers. The CDRH has proposed a significant shift in how establishment fees—the annual costs paid by companies to register their facilities with the FDA—are levied. The agency’s proposal involves splitting establishment fees between domestic and foreign firms, with overseas companies paying a higher rate.
This "two-tier" system is intended to reflect the higher costs associated with inspecting and regulating international facilities. However, the proposal has met with resistance from medtech lobbyists who represent global corporations. These advocates have urged the FDA to consider existing trade obligations, specifically the United States-Mexico-Canada Agreement (USMCA), when setting these fees. They argue that imposing higher fees on Canadian and Mexican firms could violate the spirit, if not the letter, of the "national treatment" provisions in the trade pact. According to the latest meeting minutes, the CDRH has so far declined to adjust its proposal based on USMCA considerations, maintaining that the fee structure is a matter of regulatory cost recovery rather than trade policy.
The Technical Battle Over Spending Triggers
Perhaps the most complex aspect of the current negotiations involves the "appropriations and spending triggers." These are statutory safeguards designed to ensure that industry user fees do not replace public funding for the FDA. Under current law, the CDRH is prohibited from spending the user fees it collects unless two conditions are met:
- The Appropriation Trigger: Congress must provide a minimum baseline of funding for the CDRH through the general budget.
- The Spending Trigger: The center must actually spend a specific amount of non-user-fee funding on device reviews and related activities.
In December, the FDA proposed sweeping changes to both thresholds. The agency argued that the current triggers are too rigid and do not account for years in which congressional appropriations fail to increase at the same rate as the agency’s costs. Specifically, the FDA wants to increase the "threshold of miss"—the margin by which the spending trigger can be missed without halting the use of user fees—and adopt an agency-wide appropriation trigger rather than one specific to the CDRH.
Industry groups have expressed strong opposition to these changes, with the exception of minor technical corrections. The industry view is that these triggers are essential for holding Congress accountable for its share of the FDA’s budget. If the triggers are loosened, lobbyists fear that lawmakers will feel less pressure to provide adequate public funding, eventually leading to a scenario where the medtech industry is the primary financier of its own regulator—a dynamic that could lead to conflicts of interest or an unsustainable financial burden on smaller firms.
Historical Context and MDUFA Timeline
The MDUFA program was first established by Congress in 2002 to speed up the medical device review process. Before the program’s inception, the FDA relied solely on congressional appropriations, which often fluctuated and led to significant backlogs in device approvals. By allowing the FDA to collect fees from the companies submitting devices for review, the program provided a stable stream of revenue to hire more reviewers and modernize IT systems.
The program is reauthorized every five years. The current iteration, MDUFA V, was hailed as a landmark agreement when it was finalized in 2022, as it significantly increased the total funding to over $1.7 billion and introduced the aforementioned hiring incentives. However, the subsequent federal layoffs and shifting economic conditions have made the MDUFA V targets difficult to achieve.
The timeline for the MDUFA VI negotiations is tight. The FDA and industry stakeholders must reach a consensus and submit a finalized agreement to Congress later this year. This allows for the legislative process to conclude well before the current agreement expires in September 2027. If an agreement is not reached in time, the FDA could face a "funding cliff," potentially leading to furloughs of review staff and a total halt in the processing of new medical device applications.
Implications for Innovation and Public Health
The outcome of these negotiations will have a profound impact on the medical device ecosystem. If the FDA succeeds in its bid for less granular staffing reporting and more flexible spending triggers, it will gain operational autonomy but may face increased skepticism from the industry regarding its efficiency. Conversely, if the industry wins its fight for office-level transparency, it could lead to more targeted improvements in review times for critical technologies like AI-driven diagnostics or advanced robotic surgery tools.
The debate over international fees also carries significant weight for the supply chain. Higher fees for overseas firms could discourage smaller international innovators from entering the U.S. market, potentially limiting the options available to American doctors and patients. On the other hand, if domestic firms feel they are subsidizing the regulation of their foreign competitors, it could lead to political pressure for more protectionist regulatory policies.
As the February 11 meeting concluded, both sides remained far apart on the most technical fiscal provisions. The industry has requested more clarity on the FDA’s proposed changes to the appropriations trigger and is expected to provide formal feedback in upcoming sessions. With the 2027 deadline approaching, the pressure is mounting to find a middle ground that ensures the FDA remains both well-funded and strictly accountable to the stakeholders who provide that funding.